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An indirect immunofluorescence assay (IFA) was used to identify patients with antibodies reactive to the
human granulocytic ehrlichiosis (HGE) agent. Serum samples collected from clinically ill individuals were
submitted to the Centers for Disease Control and Prevention by physicians via state health departments from
throughout the United States and tested against a panel of ehrlichial and rickettsial pathogens. Antibodies
reactive to the HGE agent were detected in 142 (8.9%) of 1,602 individuals tested. There were 19 confirmed and
59 probable (n 5 78) cases of HGE as defined by seroconversion or a fourfold or higher titer to the HGE agent
than to the Ehrlichia chaffeensis antigens. The average age of patients with HGE was 57 years, and males
accounted for 53 (68%) of the patients. Cases of HGE occurred in 21 states; 47 (60%) of the cases occurred in
Connecticut (n 5 14), New York (n 5 18), and Wisconsin (n 5 15). Onset of HGE was identified from April
through December, with cases peaking in June and July. The earliest confirmed cases of HGE occurred in 1987
in Wisconsin and 1988 in Florida. No fatalities were reported among the 78 patients with confirmed or probable
HGE. Reactivity to the HGE agent and to either Coxiella burnetii, Rickettsia rickettsii, or Rickettsia typhi was
infrequent; however, 74 (52%) of the 142 individuals who were positive for HGE had at least one serum sample
that also reacted to the E. chaffeensis antigen. Thirty-four persons with confirmed or probable human monocytic
ehrlichiosis due to E. chaffeensis also had antibodies to the HGE agent in at least one serum sample. The spe-
cific etiologic agent for 30 patients was not ascribed because of similarity of titers to both ehrlichial antigens.
The use of both antigens may be required to correctly diagnose most cases of human ehrlichiosis, especially in
geographic regions where both the HGE agent and E. chaffeensis occur.
Human granulocytic ehrlichiosis (HGE) was first described
in 1994 for a series of 12 patients residing in Minnesota or
Wisconsin (4, 12). HGE is a febrile illness characterized by
headache, myalgia, malaise, thrombocytopenia, leukopenia,
and elevated levels of hepatic transaminases (5). HGE is clin-
ically indistinguishable from human monocytic ehrlichiosis
(HME), which is caused by Ehrlichia chaffeensis (2). As of May
1998, approximately 350 cases of HGE (four of which resulted
in death) had been recognized in the United States (4, 21, 26,
30). The HGE agent is closely related to (or conspecific with)
Ehrlichia equi, the agent of equine ehrlichiosis, and Ehrlichia
phagocytophila, the agent of tick-borne fever in ruminants (15,
18, 47).
HGE is a zoonotic disease, and its natural history is still
being defined. The blacklegged tick, Ixodes scapularis Say (in-
cluding the species formerly known as Ixodes dammini Spiel-
man, Clifford, Piesman, and Corwin [40]), is believed to be a
principal biological vector of the HGE agent in the regions
where this tick occurs (30, 41, 48, 49). Peromyscus leucopus, the
white-footed mouse, is a competent reservoir host (48). Addi-
tional tick vectors or vertebrate host species maintain the HGE
agent in some locations, such as northern California, where I.
scapularis does not exist. Serologic evidence suggests that
HGE-like agents occur in additional rodent species and in
regions outside of the areas where HGE is currently recog-
nized (39). It is possible that the agent is maintained in nature
in a tick-rodent cycle similar to the Borrelia burgdorferi main-
tenance cycle, with humans being involved only as incidental
dead-end hosts (31).
The Centers for Disease Control and Prevention (CDC) has
made serologic testing for HGE available for state health de-
partments since August 1995, following an investigation of 29
confirmed or probable cases of HGE in Westchester County,
N.Y. (9). Before 1996, several strains of granulocytic ehrlichiae
grown in horse neutrophils were used as antigens for testing for
HGE by indirect immunofluorescence assay (IFA) at the CDC
and elsewhere because the HGE agent had not yet been iso-
lated and maintained in cell culture. The close genetic and
antigenic similarities between these agents resulted in consid-
erable cross-reactivity of human antibodies, which is sufficient
to identify cases of HGE (15). Antigens produced in experi-
mentally infected horses are still used for testing for HGE by
some institutions and commercial laboratories. The HGE
agent was recently isolated and adapted to cell culture (24, 38),
and IFAs that use cell culture-derived antigens have been
developed (38, 43). These assays offer several advantages over
assays that use horse-derived antigens and are being increas-
ingly used for testing for HGE. An assay developed at the CDC
(38) was used to test serum samples from individuals with
suspected rickettsial and ehrlichial illnesses for antibodies to
the HGE agent.
MATERIALS AND METHODS
Acquisition of samples. Serum samples from patients with suspected rickettsial
and ehrlichial illnesses were submitted to the Viral and Rickettsial Zoonoses
Branch, CDC, by physicians through their state health departments from through-
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Disease Control and Prevention, 1600 Clifton Rd., Mailstop G-13,
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out the United States. Serum samples were stored at 4°C or were retrieved from
storage at 270°C prior to being tested for HGE. Retrospective testing back to
1987 was conducted on all available samples from seven states where the HGE
agent is known or suspected to be endemic (California, Connecticut, Florida,
Maryland, Minnesota, New York, and Wisconsin). Prospective testing for HGE
began in August 1995 on samples submitted from any state for any rickettsial or
ehrlichial antibody evaluation.
HGE agent antigens. Two sources of antigen were used for HGE testing.
Commercially available antigen dotted onto Teflon-coated microscope slides
(Spirochete and Rickettsia Laboratory, University of California School of Vet-
erinary Medicine, Davis) was used until April 1996. These slides had been pre-
pared with infected neutrophils harvested from a horse experimentally infected
with the BDS strain of the HGE agent (36). This antigen was used to test 440
serum samples in this study.
Serum samples received after April 1996 were tested with the USG3 isolate of
the HGE agent grown in HL-60 cell culture as the antigen. This antigen has been
shown to be sensitive and specific for detecting antibodies to the HGE agent
(38). Because the HGE antigen produced in horses previously gave results
comparable to those with the cell culture-derived HGE antigen when the same
human serum samples were tested with both antigens (38), the results were
combined in the present analysis.
Serologic assay. Serum samples were tested by an IFA that has been previ-
ously described (38). Prior to use, antigen slides were removed from storage at
270°C, placed into a desiccator, and allowed to warm to room temperature. To
screen the samples, serial twofold dilutions were made and two dilutions (1/64
and 1/128) were placed onto 18- or 24-well, Teflon-coated microscope slides
(Erie Scientific Co., Portsmouth, Maine). Slides were placed in a humidified plas-
tic chamber and incubated for 30 min at 37°C and then washed three times for
5 min each time in phosphate-buffered saline, pH 7.4. An optimized dilution
(1/100) of fluorescein isothiocyanate (FITC)-labeled goat anti-human conjugate
specific to the heavy and light chains of human immunoglobulin G (IgG) (Kirke-
gaard & Perry Laboratories, Inc., Gaithersburg, Md.) was then applied to the
slides. Slides were incubated and washed as before, except that 3 to 4 drops of a
1.65% solution of eriochrome black T in water was added to the middle wash as
a counterstain. Glycerol-based antifade mounting medium was added to each
well, a coverslip was applied, and the slides were read by using UV illumination.
Any reactive samples were then titrated to endpoint with an optimized dilution
(1/150) of FITC-labeled goat anti-human conjugate specific to the gamma chain
of human IgG (Kirkegaard & Perry Laboratories, Inc.). Antibody titers were
confirmed by a second microscopist reading coded slides. Titers are reported as
the reciprocal of the highest dilution showing specific ehrlichial fluorescence. In
this study, a titer of 64 or greater to the HGE agent was considered to be positive
evidence of specific antibody (10).
Reactivity with other antigens. Serum samples usually had been tested against
other rickettsial antigens, and titers to the HGE agent were compared with titers
to Coxiella burnetii phase II (causative agent of Q fever), Ehrlichia canis (canine
ehrlichiosis), E. chaffeensis (HME), Rickettsia rickettsii (Rocky Mountain spotted
fever), and Rickettsia typhi (endemic typhus). E. canis had been used as an
antigen for the diagnosis of HME until 1991, when E. chaffeensis was isolated and
maintained in cell culture; the results were combined for the analysis (14). Titers
to these additional antigens were obtained by review of CDC records. Occasion-
ally, endpoint titration had not been done, and for these samples the highest titer
obtained was used in the calculation of geometric mean titers (GMT). FITC-
labeled goat anti-human conjugate specific to the heavy and light chains of
human IgG was used for testing against these antigens by IFA.
Case definition. The surveillance definition for human ehrlichiosis requires the
presence of an illness clinically compatible with human ehrlichiosis with labora-
tory confirmation (10). Laboratory confirmation of human ehrlichiosis requires
the presence of at least one of the following: a fourfold or greater change in the
titer of antibody to Ehrlichia spp. antigen by the IFA test in paired acute- and
convalescent-phase serum samples (including a change in titer of ,64 to $64);
a positive PCR assay result; and identification of intracytoplasmic morulae in
stained blood, bone marrow, or cerebrospinal fluid leukocytes together with an
IFA titer of $64. Because of incomplete data on the forms accompanying the
samples, it was often difficult to determine whether an illness compatible with
human ehrlichiosis was present. Signs and symptoms for rickettsial and ehrlichial
diseases are similar in many regards (e.g., headache, fever, malaise, arthralgia,
thrombocytopenia, and elevated levels of transaminases). In this report, we have
assumed that because the samples were submitted for testing against a panel of
rickettsial and ehrlichial antigens, the patient was ill with symptoms that were
clinically compatible with human ehrlichiosis.
Because we observed that a significant proportion of samples reacted with
both the HGE agent and E. chaffeensis antigens, we used a fourfold difference in
maximum titer to either antigen to ascribe etiology for individuals with dually
reacting samples. A fourfold difference has been used to differentiate infection
among numerous rickettsial and ehrlichial agents in several studies (28, 38, 42).
In this study, a confirmed case of HGE was defined as illness in an individual
whose paired serum samples exhibited a fourfold rise or fall in titer of antibody
to the HGE agent (with a titer of $64 in at least one serum sample) or a change
in titer from ,64 to $64. A probable case of HGE was considered to be illness
in an individual with a single titer of $64 to the HGE agent or who had paired
serum samples that differed in titer by less than a fourfold dilution. These
classifications included individuals who were simultaneously seropositive for E.
chaffeensis in one or more serum samples if the maximum titer of antibody to the
HGE agent, obtained from any sample, was fourfold or higher than the maxi-
mum titer of antibody to E. chaffeensis. Similarly, cases were classified as con-
firmed or probable HME if the maximum titer to E. chaffeensis, obtained from
any sample, was fourfold or greater than those to the HGE agent. If there was
a less than fourfold difference in maximum titers between antigens, individuals
were classified as having human ehrlichiosis (agent undetermined). In some
instances, comparison of titers to the HGE agent and other rickettsial agents
suggested a different etiologic cause of the disease, even though the patient met
our case definition for HGE.
Epidemiologic comparisons. Epidemiologic information was often incomplete
or absent from the forms accompanying samples; however, most reports included
demographic information (sex, age, state of origin). Clinical information (date of
onset, signs and symptoms, laboratory findings) was reported less often. Because
usually only the presence and not the absence of signs and symptoms was noted
(i.e., the denominator was unspecified), we report these findings only on the basis
of frequency of reporting and not on the basis of percentages of occurrence in all
cases.
RESULTS
Number of confirmed and probable cases of HGE. A total of
2,251 serum samples were obtained from 1,602 individuals for
HGE testing. A total of 142 individuals (8.9%) had at least one
serum sample that reacted with the HGE agent antigen at a
titer of $64. Titers of $64 were obtained from 184 (78%) of
the 235 samples that were available for testing from these 142
individuals. Nineteen confirmed and 59 probable cases of HGE
were detected. Among the 19 confirmed cases, 15 (79%)
had fourfold or greater increases in titer. Twelve of the first
samples from these confirmed cases were seronegative (IFA
titer of ,64), and three were seropositive (titers of 64, 512, and
512). Titers obtained from the second samples of these 12
patients had a GMT of 706 (range, 64 to 4,096), and titers
obtained from the second sample of the three individuals who
were initially seropositive rose to 1,024, 2,048, and 4,096, re-
spectively. The four remaining confirmed cases had fourfold or
greater decreases in titer. The first samples of these individuals
had a GMT of 1,448 (range, 128 to 65,536), and the second
samples had titers of ,64, ,64, 512, and 1,024. It was uncom-
mon for more than two samples to be submitted from the same
individual, as only 52 third samples and 7 fourth samples were
identified.
Geographic distribution of cases of HGE. Confirmed or
probable cases of HGE were detected in samples submitted
from 21 states and from the District of Columbia (Table 1).
Most of the patients (47 of 78, 60%) resided in three states
where HGE is endemic: Connecticut (n 5 14), New York (n 5
18), and Wisconsin (n 5 15). However, samples from patients
with confirmed or probable HGE originated from several
states where HGE has infrequently or never before been re-
ported (Georgia, Kentucky, Hawaii, Missouri, Montana, Okla-
homa, Tennessee, Washington, and West Virginia) (Table 1).
The overall prevalence of antibodies to the HGE agent among
individuals with suspected rickettsial and ehrlichial illnesses
from the seven states selected for retrospective surveillance
was 7.7% (62 individuals with confirmed or probable cases of
809 individuals tested) and varied from 1.6% in California and
Maryland to 23.7% in Connecticut (Table 1).
The earliest serologically confirmed cases of HGE as deter-
mined retrospectively occurred in July 1987 (the earliest year
tested) in Wisconsin (titers of ,64 and 512) and in September
1988 in Florida (titers of 512 and 2,048). Both patients had
cases of suspected ehrlichial illness yet tested negative for
E. canis, C. burnetii, R. rickettsii, and R. typhi in all samples. The
greatest number of cases (n 5 18) occurred in 1994 and was
due in large part to the contribution of serum samples from
patients from New York (9 patients) and Connecticut (4 pa-
tients). In 1995, when testing from any state was initiated, 12
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confirmed or probable cases of HGE were detected, and in
1996, the last year for which there are complete data, 15 cases
were detected. There were no reported fatalities among the
142 individuals who had at least one positive antibody titer to
the HGE agent.
Approximate interval for antibody patency of HGE cases.
The time of disease onset was reported for 46 of the 78 patients
with confirmed or probable HGE. Eleven (65%) of 17 individ-
uals who had serum samples submitted during the first week
following onset of illness had positive samples, as did 10 (91%)
of 11 individuals who had samples submitted during the second
week (Fig. 1). These individuals represented 14 and 13% of the
confirmed or probable cases of HGE, respectively. Every sam-
ple from patients with confirmed or probable HGE that was
submitted after 2 weeks of illness was seropositive, with the
exception of two samples from individuals who became sero-
negative by day 21 (doxycycline given on the day of onset) and
day 178 (no data for antibiotic therapy reported) following the
onset of illness. Overall, 91% (n 5 42) of the confirmed or
probable cases of HGE for which the date of onset of symp-
toms was reported were diagnosed by the identification of one
or more positive serum samples within the first 3 months fol-
lowing the onset of the disease. However, in four cases, the first
serum samples received at the CDC were positive and were
obtained at 92, 254, 277, and 344 days after disease onset (Fig.
1).
GMT were comparatively lower when antibodies were de-
tected during the first week of illness (n 5 11, GMT 5 187).
Titers among positive samples submitted during the second
week of illness rose substantially (n 5 10, GMT 5 588), and
the GMT then varied between 416 (weeks 3 and 4) and 861
($3 months) (Fig. 1).
FIG. 1. Development of titers of antibody to the HGE agent in 46 patients
with confirmed or probable HGE for whom data were available. The solid bars
represent the GMT for the indicated periods.
TABLE 1. Prevalence of confirmed and probable cases of HGE from throughout the United Statesa
State No. of individualstested for HGE
No. of confirmed or
probable cases of
HGE (prevalence %)
No. of confirmed or probable
cases of HME also reactive
with the HGE agent
No. of confirmed or probable
cases of human ehrlichiosis
(agent undetermined)
California 62 1 (1.6) 3
Connecticut 59 14 (23.7) 2
Florida 138 7 (5.1) 8 2
Georgia 25 2 (8.0) 1
Hawaii 22 1 (4.5) 1
Kentucky 13 1 (7.7) 1 1
Maine 3 1 (33.3) 1
Maryland 189 3 (1.6) 5 3
Massachusetts 71 1 (1.4) 1
Minnesota 47 4 (8.5)
Missouri 52 1 (1.9) 3 2
Montana 21 1 (4.8) 1
New Jersey 5 1b (20.0)
New York 151 18 (11.9) 1 1
Oklahoma 15 1 (6.7) 1
Pennsylvania 9 1 (11.1) 1 1
Rhode Island 6 2 (33.3)
Tennessee 41 1 (2.4) 2
Texas 21 1 (4.8)
West Virginia 3 1 (33.3) 1
Wisconsin 163 15 (9.2) 1
Total 1,116 78 (7.0) 22c 22d
a Based on analysis of serum samples submitted to the CDC for testing against a panel of rickettsial agents between 1987 and 1997. In addition, a probable case of
HGE among serum samples from 198 healthy blood donors was detected in Washington. An additional 450 patients were negative for HGE (titers of ,64) from the
following states and the District of Columbia: Alabama (n 5 87), Arkansas (n 5 38), Arizona (n 5 6), Colorado (n 5 9), District of Columbia (n 5 11), Delaware
(n 5 9), Iowa (n 5 17), Illinois (n 5 15), Indiana (n 5 17), Kansas (n 5 1), Louisiana (n 5 5), Michigan (n 5 16), Mississippi (n 5 2), North Carolina (n 5 57), Nebraska
(n 5 22), New Hampshire (n 5 4), New Mexico (n 5 7), Nevada (n 5 2), Ohio (n 5 13), Oregon (n 5 47), South Carolina (n 5 10), Utah (n 5 3), Virginia (n 5
37), Washington (n 5 12), and Wyoming (n 5 3). States of origin of 36 patients who were negative for HGE were not identified. Seven states were selected for
retrospective testing: California, Connecticut, Florida, Maryland, Minnesota, New York, and Wisconsin.
b This likely was a case of Rocky Mountain spotted fever (see the text).
c In addition, 10 confirmed or probable cases of HME were detected in the following states: Alabama (n 5 1), Arkansas (n 5 1), Delaware (n 5 1), Illinois (n 5
1), Mississippi (n 5 1), North Carolina (n 5 3), and South Carolina (n 5 2). Two confirmed or probable cases were also detected in the District of Columbia.
d In addition, eight cases of human ehrlichiosis (agent undetermined) were detected in Alabama (n 5 1), Arkansas (n 5 1), Delaware (n 5 1), North Carolina (n 5
2), and the District of Columbia (n 5 1); samples from two cases were submitted from commercial laboratories, and the states of origin for these samples are unknown.
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Seasonal distribution of HGE cases. The earliest onset of
illness for a patient with probable or confirmed HGE was
recorded in April, and a strong summer peak followed, as 21
(46%) of the 46 patients for whom the date of onset was
reported occurred in June and July (Fig. 2). Onset of illness
was reported throughout the fall and through December; no
cases were identified from January through March.
Demographic, clinical, and exposure histories for HGE pa-
tients. Among the 78 patients with confirmed or probable
HGE, the average age was 56.8 years (n 5 65; median, 61
years; range, 3 to 88 years). Males accounted for 53 (67.9%) of
the 78 patients with HGE.
Fever was the most commonly reported sign (46 cases),
followed by headache (25 cases) and myalgia (17 cases); less
commonly noted signs were malaise (6 cases), nausea (6 cases),
vomiting (7 cases), diarrhea (8 cases), and chills (8 cases).
Fourteen of the 78 patients received doxycycline treatment.
Other antibiotics received by patients with HGE included
ceftriaxone, ceftazidime, ciprofloxacin, and vancomycin.
Thrombocytopenia was the most commonly reported clini-
cal laboratory finding (22 cases), followed by leukopenia (18
cases) and elevated hepatic transaminases (8 cases). Presence
of intracytoplasmic microcolonies (morulae) was recorded in
four cases.
Tick bites were recorded for 13 individuals; 7 other individ-
uals reported exposure to ticks, but no tick bite was specified.
One additional individual reported sustaining a cut while dress-
ing a deer.
Reactivity to other antigens among HGE-positive samples.
Reactivity to one or more rickettsial and ehrlichial antigens
was noted among the 184 samples that were positive for the
HGE antigen (Table 2). The greatest reactivity among those
samples that were positive for the HGE antigen occurred with
the E. chaffeensis antigen, both in percentage of samples pos-
itive at titers of $64 (53.8%) and in GMT (694). Reactivity
with both the HGE and E. chaffeensis antigens occurred in
samples from 74 individuals, 10 (13.5%) of whom had con-
firmed or probable HGE. The remaining 64 individuals were
classified as having either confirmed or probable HME (n 5
34) or human ehrlichiosis (agent undetermined) (n 5 30) (see
below).
The reactivities of 2,128 serum samples that were tested for
both the HGE agent and the E. chaffeensis antigens were ex-
amined in detail (Table 3). Of these, 1,711 samples were se-
ronegative for both antigens. Of the 417 samples that were
positive for one or both ehrlichial antigens, 319 (76.4%) sam-
ples reacted to only one antigen: 248 samples from 173 patients
with confirmed (n 5 45) or probable (n 5 128) HME reacted
only to the E. chaffeensis antigen (GMT 5 181; titer range, 64
to 32,768), and 71 samples from 68 patients with confirmed or
probable HGE reacted only to the HGE agent antigen
(GMT 5 330; titer range, 64 to 65,536). Reactivity to the HGE
agent antigen among all samples that were positive for the
E. chaffeensis antigen was only half as common (98 of 346
samples, 28%) as was reactivity to the E. chaffeensis antigen
among all samples that were positive for the HGE agent (98 of
169 samples, 58%). However, the proportions of patients with
serum samples that reacted to both antigens were similar for
both agents: 10 (12.8%) of the 78 patients with HGE had
samples that reacted to both antigens, while 34 (16.4%) of the
207 patients with HME had samples that reacted to both an-
tigens. Among the 98 samples that reacted to both antigens,
the GMT of antibody to E. chaffeensis was 694 (range, 64 to
131,072), more than twice as high as the GMT of antibody to
the HGE agent (GMT 5 306; range, 64 to 4,096). On the basis
of a fourfold or greater difference in maximum titers of anti-
bodies to the HGE agent and to E. chaffeensis, there were 15
confirmed and 19 probable cases of HME that reacted to both
antigens. These cases were identified from 17 states and the
District of Columbia (Table 1).
There were 30 individuals who represented confirmed or
probable cases of human ehrlichiosis but for whom the specific
FIG. 2. Distribution of confirmed and probable cases of HGE in the United
States by month of onset (n 5 47).
TABLE 2. Reactivities of serum samples that were seropositive for
both the HGE agent (GMT 5 280; titer range, 64 to 65,536) and
for other ehrlichial and rickettsial antigens
Antigen No.testeda
No.
reactive
%
reactive
GMTb
(range)
Ehrlichia chaffeensis 182 98 53.8 694 (64–131,072)
Coxiella burnetii 111 9 8.1 203 (64–$512)
Rickettsia rickettsii 182 16 8.8 235 (64–$2,048)
Rickettsia typhi 110 8 7.3 70 (64–512)
a Not all serum samples positive for the HGE agent were tested against all
other antigens; therefore, numbers tested vary.
b IFA titers of $64 to the respective antigens.
TABLE 3. Distribution of titers of antibodies to the HGE agent
and to E. chaffeensis based on paired testing
of 2,128 serum samplesa
Titer to
E. chaffeensis
Titer to the HGE agent
,64 64 128 256 512 1,024 2,048 4,096
,64 1,711 18 12 8 12 9 8 4
64 97 5 2 2 1 1 1
128 55 6 1 3 1
256 33 4 4 1 3
512 24 4 3 2 7 1 1
1,024 14 2 2 1 1 1 2
2,048 14 3 6 4 5 3 1
4,096 3 1 1 1 1
8,192 5 2 2 1 1
.16,384 3 1 2 1
a Multiple samples from individuals were included when available. The boxed
area represents 37 dually reactive serum samples that were less than fourfold
different in their titers of antibodies to both antigens. The titer of antibodies to
the HGE agent was fourfold higher than the titer of antibodies to E. chaffeensis
in 13 samples above the boxed area, whereas the titer of antibodies to
E. chaffeensis was fourfold higher than the titer of antibodies to the HGE agent
in 48 samples below the boxed area.
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etiologic agent was not ascribed due to less than fourfold
differences in maximum titers of antibodies to the HGE agent
and to E. chaffeensis. These cases were identified from 16 states
and the District of Columbia (Table 1).
Possible dual infections with other agents. Reactivity to
the HGE agent and to either C. burnetii, R. rickettsii, or R. typhi
antigens was less frequent (7 to 9% of the HGE-positive sam-
ples) than was reactivity to both the HGE agent and the
E. chaffeensis antigens (54 of the HGE-positive samples); the
GMT to these antigens were also lower (Table 2). However, in
some instances, the titers to these agents approached or ex-
ceeded those to the HGE agent. Under different study criteria,
these individuals would be interpreted as having evidence of
current or past infection with a different agent. The HGE
patient from West Virginia had an antibody titer of 4,096 to
the HGE agent and an antibody titer of $512 to C. burnetii
(phase II) in the same sample. Two HGE patients from New
York had identical maximum titers of antibodies to both the
HGE agent and C. burnetii of 512, and a third patient from
New York had a titer of antibody to the HGE agent of 128 and
a titer of antibody to C. burnetii (all phase II) of 512. The HGE
patient from New Jersey had a titer of antibody to the HGE
agent of 64 but also had a titer of antibody to R. rickettsii of
$2,048. The patient from Pennsylvania had maximum titers of
antibody to the HGE agent and to R. rickettsii of 128 and 512,
respectively, while another patient from New York had corre-
sponding titers of 256 and $2,048, respectively.
DISCUSSION
We have previously shown that the lack of a serologic assay
caused cases of HGE to be missed (38). The present study
identified 78 confirmed or probable cases of HGE from 21
states. Most of these cases were identified by retrospective
analysis of samples submitted from four states where HGE is
known to be endemic: Connecticut, Minnesota, New York, and
Wisconsin (4, 5, 9, 11, 26). However, patients with antibodies
reactive to the HGE agent were identified among specimens
received from several states where this disease has not previ-
ously been identified or has been infrequently reported (Geor-
gia, Hawaii, Kentucky, Maine, Missouri, Montana, Oklahoma,
Tennessee, Texas, Washington, and West Virginia). Because
travel histories were not provided for most of the patients from
the latter states, it was not possible from the report forms to
determine where all exposures might have occurred and there-
fore whether HGE is actually endemic to the state from which
the sample was submitted. In two instances, travel and tick
exposure histories were noted on the submitted forms. The
single patient with HGE from Texas reported an exposure to
ticks in Minnesota, and the patient from Maine experienced
tick exposure in Massachusetts, both states of known endemic-
ity for HGE (4, 48). Similarly, an HME patient from Hawaii
had been bitten by ticks while travelling in Texas. These cases
indicate that the determination of HGE and HME endemicity
will require more detailed case investigations and clearly illus-
trate the need for health providers to be alert to travel and
exposure histories. As the human ehrlichioses are becoming
notifiable in many states (11), it is hoped that the collection of
information of this kind will become routine.
Of interest, seven cases of HGE were identified among Flor-
ida residents, and cases of HGE were found to have occurred
there as early as 1988. Serologic evidence of granulocytic ehr-
lichial infections in rodents has been reported from Florida
(39). E. equi was reported from a Florida horse infested with
I. scapularis in 1984 (8). The occurrence of additional HGE
cases in Florida suggests that the HGE agent may be endemic
to that state and is possibly transmitted by local populations of
I. scapularis. HME also occurs in Florida, and we identified
eight additional cases of HME there. Amblyomma americanum
is thought to be the vector of E. chaffeensis (3, 19, 32, 33).
The extensive dual reactivity to the HGE agent and E. chaf-
feensis antigens and the occasional reactivity to other antigens
suggest that some infected individuals might have been ex-
posed to more than a single rickettsial agent. Reactivity to the
HGE agent likely represents cross-reactive antibodies resulting
from infection with the other agents (37, 50). As previously
mentioned, the presence of HGE in certain states is not accu-
rately documented in the present study because of the lack of
travel and exposure histories. As an example, the “case” of
HGE from New Jersey was in all probability a case of Rocky
Mountain spotted fever (titers of antibody to R. rickettsii of
$2,048 and 256 in the first and second samples, respectively)
with the presence of low titers of antibodies (titer of 64 in both
samples) to the HGE agent. A single, probable case of HGE,
based on a single titer of 64, was detected in California, where
HGE has been previously reported from the northern part of
the state (22, 23) and where E. equi is endemic (25, 34, 35).
Probable cases of HGE in Hawaii, Kentucky, Missouri, Mon-
tana, Oklahoma, Tennessee, and Washington were based on
maximum titers of 64 or 128. The problem of potential cross-
reactivity of antibodies, the possibility of dual or past infec-
tions, the clinical and epidemiologic similarities of the ill-
nesses, and the difficulty in obtaining accurate travel and
exposure histories from some patients indicate that additional
testing will be required to confirm the presence of HGE in
these states.
There are limitations in ascribing etiology based on the com-
parison of titers obtained by using different IFAs and different
antigens (E. chaffeensis, the HGE agent, and previously E. ca-
nis and E. equi). However, when varied reactivity to multiple
ehrlichial antigens is observed, etiologic determination based
on fourfold differences in titers of antibodies to different an-
tigens has been supported by PCR studies (13) and serologic
data (28, 38). Taking these limitations into account, the ma-
jority of the data generated on HGE in this report are consis-
tent with what is currently understood about its geographic
distribution and clinical presentation (5, 11).
Although clinical histories were missing or incomplete for
many of the patients, the most commonly observed clinical
signs, symptoms, and clinical laboratory findings for HGE in
the present study (fever, headache, myalgia, thrombocytope-
nia, and leukopenia) were similar to those reported previously
(1, 4, 5). Cases identified as HGE occurred more commonly in
males (67.9%) than in females, a finding that is also seen with
patients who have been diagnosed with HME (17). The me-
dian age of the HGE patients in this study was 61 years (mean,
57), a finding consistent with reports from Connecticut and
New York describing the median and mean ages of patients
with HGE as $50 years (1, 9, 11). The median age for cases of
HME has been younger (44 years) (20). Why HGE occurs or
is recognized in older individuals more commonly than HME
is currently not understood, but differences in the levels of
severity of the disease caused is a probable explanation.
Among the 142 individuals in the present study, dual reac-
tivity occurred in cases of HME (34 of 207 confirmed or prob-
able cases of HME, 16.4%) slightly more often than did dual
reactivity among confirmed or probable cases of HGE (10 of
78 confirmed or probable cases of HGE, 12.8%). This obser-
vation was also reflected in the higher GMT of antibodies to
E. chaffeensis antigen (694) compared with that of antibodies
to the HGE agent (306) among the dually reactive samples.
Assessment of the proportion of dually reactive serum samples
562 COMER ET AL. J. CLIN. MICROBIOL.
among cases of HGE and HME in this study should be inter-
preted with caution because of potential biases in the selection
of samples that were included. Oversampling of specimens
from states where HGE is endemic may have been offset by the
inclusion of samples from all states in prospective testing, but
we made no effort to correct for this sampling scheme. Re-
gardless of this potential bias, significant dual reactivity oc-
curred in cases of both HGE and HME in the present study.
The 37 serum samples that were less than fourfold different
in titers of antibodies to the HGE agent and to E. chaffeensis
antigens resulted in our inability to ascribe etiology for 30
(21%) of the 142 individuals positive for HGE in this study.
Thus, dual reactivity among the serum samples caused signif-
icant diagnostic confusion in determining exact etiology in
some suspected cases of ehrlichiosis. Although this limitation is
important for elucidating the epidemiologic distinctions be-
tween HGE and HME, it has no impact on the practical treat-
ment of ehrlichiosis, as doxycycline is the drug of choice for
both diseases (11). One potential issue for surveillance pur-
poses is that the current Council of State and Territorial Ep-
idemiologists’ case definition for ehrlichiosis does not directly
address the issue of serum samples that react to both the HGE
agent and E. chaffeensis (10). The potential for simultaneous
seroconversion to both agents, as well as the unique reactivity
to a single antigen among many specimens, underscores the
need to test serum samples against both ehrlichial agents when
suspected ehrlichiosis cases are confirmed by IFA. This re-
quirement may be essential in states where both agents and
their respective tick vectors occur (e.g., Connecticut, Florida,
Maryland, and New York). As previously illustrated by case
histories (including travel), a general awareness of the limita-
tions of serologic testing is important.
Although tick exposure or bite was indicated in only one-
fourth of the probable and confirmed HGE cases, the peak in
seasonal distribution of cases coincides with the peak in activity
of host-seeking nymphs of I. scapularis in the northeastern
United States (45). These data are consistent with the hypoth-
esis that the nymphal stage of I. scapularis is the most impor-
tant life stage in the transmission of the HGE agent in areas
where this vector occurs (5). Tick bites being unreported for
patients with a tick-borne disease is a widespread phenomenon
and is well documented in studies of Lyme disease (46) and
Rocky Mountain spotted fever (27). Cases of HGE were also
identified in the late fall and early winter into December, which
coincides with the onset of the activity of adult I. scapularis in
the Northeast (45) and upper Midwest (29). The late fall and
early winter transmission of the HGE agent is in contrast to the
transmission cycle of E. chaffeensis. Reports of illness associ-
ated with E. chaffeensis infections begin in April, peak in mid-
summer (May through July), and generally cease by November
(16, 20). This pattern reflects the seasonal activity of A. ameri-
canum (44).
In addition to the traditional means of exposure to the HGE
agent (via a tick), exposure to deer blood was a possible mech-
anism of infection for one individual who sustained a cut while
dressing a deer. Exposure to deer blood has been hypothesized
to be the route of exposure for three men who each butchered
.250 deer carcasses in the upper Midwest in the 2 weeks prior
to their illnesses (6). Although granulocytic Ehrlichia infection
can be common among white-tailed deer in disease-endemic
areas (7), the role of deer as competent reservoir hosts of the
HGE agent is still undefined.
Over 400 cases of HGE have been described from the
United States. Most cases of HGE have occurred in the upper
midwestern states of Minnesota and Wisconsin and in several
states in New England (Connecticut, Massachusetts, New York,
and Rhode Island). HGE has been less commonly reported
from other regions, such as the West and Southeast (e.g.,
northern California and Florida). The HGE agent has been
present and presumably responsible for disease in at least two
widely separated locales in the United States (Florida and the
upper Midwest) for at least a decade. Because the disease is
easily treatable, yet potentially fatal, an increased index of
suspicion on the part of physicians is of paramount importance
in efforts to reduce morbidity caused by this agent. Increased
surveillance for ehrlichiosis, as indicated by trends toward mak-
ing these diseases nationally notifiable, should provide needed
information on the geographic extent of affected areas and
insights into variations in the epidemiologies of these diseases
across ecologically diverse regions.
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